HL-60 / HL-60-luc Orthotopic Mouse Model Service for Leukemia

The HL-60 / HL-60-luc orthotopic mouse model engrafts a human acute promyelocytic leukemia cell line into the systemic compartments of immunodeficient mice, where malignant promyelocytes home to the bone marrow, expand through the blood, and infiltrate peripheral organs much as they do in patients. Alfa Cytology operates this model across intravenous, intraperitoneal, and subcutaneous configurations, pairing monoclonal quality-controlled luciferase cells with scheduled bioluminescence imaging in vivo and marrow-level endpoint analysis, so differentiation agents, targeted inhibitors, and cell therapies are tested in a system faithful to human leukemia biology.

Overview of HL-60 / HL-60-luc Orthotopic Mouse Model for Leukemia

HL-60 is a human myeloid leukemia line with remarkable pedigree: it was first reported by Collins, Gallo, and Gallagher in Nature in 1977 and fully characterized in Blood in 1979, derived from the peripheral blood of a 36-year-old female patient originally diagnosed with acute promyelocytic leukemia (later cytochemical review argued for an FAB M2 myeloblastic classification, reflecting how closely the two entities overlap). The cells are suspended neutrophilic promyelocytes that spontaneously mature in small numbers and can be driven toward granulocytic or monocytic differentiation by dimethyl sulfoxide, retinoic acid, TPA, or vitamin D₃ — the property that made HL-60 the prototype for differentiation therapy research. Molecularly, HL-60 carries an activating NRAS codon-12 mutation and MYC amplification, among the earliest such lesions documented in a human cancer line, and retains TP53 function.

Fig 1. Longitudinal bioluminescence imaging of an HL-60-Luc orthotopic AML model following intravenous engraftment, demonstrating leukemia homing and expansion within the bone marrow, spine, and hind-limb skeletal compartments. (Lee, Eunhee, et al., 2023)

In vivo, HL-60 behaves as a faithful disseminated leukemia xenograft. Delivered intravenously — the route that best reproduces human disease — cells home to the bone marrow, with bioluminescence signals concentrating in the vertebral column, pelvis, and femurs, and then spill into blood, spleen, and liver; intraperitoneal injection instead generates peritoneal myeloid tumors, while subcutaneous inoculation produces localized chloroma masses, giving researchers three disease configurations from one cell bank. Reported challenge doses span 5 × 10⁵ to 10⁷ cells per mouse, and the HL-60-luc variant — after monoclonal selection to guarantee uniform signal — enables quantitative bioluminescence tracking in vivo, imaging-guided randomization once more than 90% of animals show engraftment, and sensitive detection of minimal residual disease and relapse after treatment withdrawal. The model has been used to validate differentiation-inducing agents, venetoclax and hypomethylating agent combinations, leukemia stem cell-directed screens, CAR-NK and other adoptive cell therapies, and oncolytic strategies.

Cell Line Information: HL-60 / HL-60-luc

HL-60 remains one of the most influential leukemia lines ever established. Its defining feature is differentiation plasticity: cultured in vitro in RPMI-1640 with 10% fetal bovine serum, the suspended promyelocytes can be nudged toward mature neutrophils by dimethyl sulfoxide or all-trans retinoic acid, or toward macrophage-like cells by TPA or 1,25-dihydroxyvitamin D₃, and even untreated cultures show low-level spontaneous maturation. The line lacks lymphoid markers, expresses myeloid antigens and Fc/complement receptors, and shows phagocytic activity that tracks with its state of differentiation. The HL-60-luc derivative carries a firefly luciferase reporter; as shown systematically for luciferase-tagged leukemia lines, monoclonal selection of high-signal clones is essential for uniform, comparable bioluminescent signals in vitro and in vivo.

Our Services

Few readouts reward rigor as directly as leukemia imaging: a well-characterized luciferase clone and a disciplined imaging schedule can turn noisy bioluminescence curves into decisive efficacy data. Alfa Cytology maintains HL-60 and HL-60-luc banks under continuous authentication and mycoplasma surveillance, and runs every study — from route selection and inoculation through flux-matched randomization, dosing, relapse monitoring, and marrow-level flow cytometry — under one quality framework, so your results remain comparable from cohort to cohort.

Workflow of HL-60 / HL-60-luc Orthotopic Mouse Model Construction

The HL-60 orthotopic procedure adapts a small number of validated published configurations to each client's therapeutic question. The workflow below outlines the standard process for constructing the model and executing an imaging-guided efficacy study.

1. Cell Expansion and Quality Control: HL-60 or HL-60-luc cells are expanded in vitro in RPMI-1640 + 10% FBS to the logarithmic phase; each batch is confirmed mycoplasma-negative and STR-authenticated, and luciferase-tagged lots are verified as monoclonal, high-signal populations by in vitro luminescence assay.
2. Host Selection and Conditioning: Female NSG, NOD-SCID, NCG, or SCID mice, 6–8 weeks of age, are acclimatized under SPF conditions for approximately one week; where study design calls for it, NSG recipients receive sub-lethal irradiation to promote engraftment.
3. Route and Dose Configuration: The administration route is matched to the disease question — intravenous for disseminated, bone marrow-homing leukemia; intraperitoneal for peritoneal tumor formation; subcutaneous for localized chloroma — with challenge doses typically between 5 × 10⁵ and 10⁷ cells per animal.
4. Inoculation: A single-cell suspension in sterile PBS is administered in a defined volume (approximately 0.2 mL intravenously via the tail vein), recording the procedure day as day −1 or day 0 according to the dosing calendar.
5. Engraftment Verification and Randomization: Bioluminescence imaging in vivo begins within the first 4–10 days; when detectable signal above background is present in more than 90% of animals, mice are randomized by total photon flux to ensure matched starting disease burdens across arms.
6. Treatment and Longitudinal Imaging: Test articles are dosed on the client-specified schedule; tumor burden is imaged twice weekly (dorsal and ventral) after intraperitoneal D-luciferin (150 mg/kg), body weights are recorded twice weekly, and post-treatment relapse is monitored weekly after dosing cessation.
7. Endpoint Analysis and Reporting: Animals reaching humane moribund criteria or a predefined day are euthanized; femoral bone marrow is flushed for flow cytometric enumeration of human leukemia cells (e.g., human CD45), spleen and liver are weighed and imaged ex vivo, blood is collected for smear analysis, and survival and imaging data are compiled into the final study report.

Fig 2. HL-60 / HL-60-luc orthotopic mouse model construction workflow.

Case Study-HL-60 / HL-60-luc Orthotopic Mouse Model Development

HL-60-based xenografts have contributed to a wide range of preclinical leukemia programs, including differentiation-inducing regimens, venetoclax and hypomethylating agent combinations, adoptive cell therapies such as CAR-NK products, and oncolytic approaches. Alfa Cytology has supported client studies on this platform across intravenous disseminated and localized configurations, with readouts combining flux-matched bioluminescence kinetics, survival analysis, and marrow-level flow cytometry. De-identified case examples and data deliverable formats can be shared on request to support your study planning.

Why Choose Alfa Cytology?

HL-60 studies succeed when cell quality, imaging discipline, and humane endpoint design align. Alfa Cytology has organized its leukemia service around those three pillars.

• A genuinely human leukemia system with APL/AML biology, including differentiation-competent cells suited to mechanism-based differentiation endpoints.
• Three validated disease configurations — intravenous disseminated, intraperitoneal, and subcutaneous chloroma — from a single authenticated cell bank.
• Monoclonal, high-signal HL-60-luc lots that keep bioluminescence curves comparable in vivo across animals and studies.
• Imaging-guided randomization at a defined engraftment threshold, eliminating burden mismatch between treatment arms.
• Differentiation-aware endpoint panels, including morphology scoring and myeloid maturation markers by flow cytometry.
• Demonstrated compatibility with cell therapy study formats, including effector-cell dosing schedules and fratricide-avoidant designs.
• Sensitive relapse monitoring after treatment withdrawal for durability and minimal residual disease assessment.

Contact Us

Whether you are testing a differentiation agent, an AML combination regimen, or an engineered cell therapy, the HL-60 / HL-60-luc orthotopic model offers a well-mapped route to credible preclinical evidence — and Alfa Cytology offers the team to run it end-to-end. Reach out to us to review route options, dosing schedules, and endpoint panels, and receive a customized study proposal within days.

For research use only. Not intended for any clinical use.